Nuvectis Pharma, Inc. — Director's Dealing 2022

May 16, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Nuvectis Pharma, Inc. (NVCT)
CIK: 0001875558
Period of Report: 2022-05-12

Reporting Person: Kaplan Matthew L. (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-05-12	Common Stock	P	1177	$15.96	Acquired	33937	Direct
2022-05-12	Common Stock	P	1823	$17.47	Acquired	35760	Direct

Footnotes

F1: Reflects the weighted average purchase price. The range of prices for the shares purchased was $15.75 to $16.00. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price.

F2: Reflects the weighted average purchase price. The range of prices for the shares purchased was $17.33 to $17.50. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price.